Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 3/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | HTR6 | P50406 | 6/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.38 |
| ▸ | HRH1 | P35367 | 5/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2816820 | 0.93 | TBXA2R (0.47) | TBXA2RHDAC1HDAC6HDAC3HDAC10 | |
| SCHEMBL2810391 | 0.90 | TBXA2R (0.55) | TBXA2RHDAC1HDAC6HDAC3HDAC10 | |
| SCHEMBL2812789 | 0.86 | HRH1 (0.48) | TBXA2RHDAC1HDAC6HDAC3HDAC10 | |
| SCHEMBL951065 | 0.84 | TBXA2R (0.43) | TBXA2RHDAC1HDAC6HDAC3HDAC10 | |
| SCHEMBL957244 | 0.82 | CYP17A1 (0.44) | TBXA2RHTR6HRH1 | |
| SCHEMBL2813152 | 0.82 | TBXA2R (0.39) | TBXA2RHDAC1HDAC6HDAC3HDAC10 | |
| SCHEMBL1722882 | 0.81 | HTR6 (0.57) | TBXA2RHTR6HRH1 | |
| SCHEMBL960009 | 0.81 | TBXA2R (0.40) | TBXA2RHTR6HRH1 | |
| SCHEMBL2813644 | 0.81 | HTR6 (0.40) | TBXA2RHTR6HRH1 | |
| SCHEMBL2815061 | 0.81 | TBXA2R (0.58) | TBXA2RHRH1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9625475-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2017-04-18 | — | — | US | claimed |
| US-20150353550-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2015-12-10 | — | — | US | claimed |
| US-20100249105-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | claimed |
| US-20100087471-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-04-08 | — | — | US | claimed |
| US-12303592-B2 | Formulations for parenteral delivery of compounds and uses thereof | WYETH, LLC (US) | 2025-05-20 | — | — | US | disclosed |
| US-20230414490-A1 | FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF | WYETH, LLC (US) | 2023-12-28 | — | — | US | disclosed |
| EP-4071151-A1 | SYRINGE CONTAINING NMTX BROMIDE | Wyeth LLC (US) | 2022-10-12 | — | — | EP | disclosed |
| EP-3608322-B1 | SYRINGE CONTAINING NMTX BROMIDE | WYETH LLC (US) | 2022-04-20 | — | — | EP | disclosed |
| US-20200179270-A1 | FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF | WYETH, LLC (US) | 2020-06-11 | — | — | US | disclosed |
| EP-3608322-A1 | SYRINGE CONTAINING NMTX BROMIDE | Wyeth LLC (US) | 2020-02-12 | — | — | EP | disclosed |
| US-10357449-B2 | — | — | 2019-07-23 | — | — | US | disclosed |
| US-9983218-B2 | Indole and indoline derivatives and methods of use thereof | ABBVIE INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20100249169-A1 | FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF | WYETH LLC (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249105-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100120813-A1 | PERIPHERAL OPIOID RECEPTOR ANTAGONISTS AND USES THEREOF | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100087471-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-04-08 | — | — | US | disclosed |
| WO-2010039851-A1 | PERIPHERAL OPIOID RECEPTOR ANTAGONISTS AND USES THEREOF | WYETH LLC (US) | 2010-04-08 | — | — | WO | disclosed |
| EP-2046388-A2 | FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080070975-A1 | Formulations for parenteral delivery of compounds and uses thereof | WYETH (US) | 2008-03-20 | — | — | US | disclosed |
| WO-2008019115-A2 | FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF | WYETH (US) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200179270-A1 | FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF | OPRL1, OPRK1, OPRM1 | TBXA2R 682/4885HDAC1 2715/4885HDAC6 245/4885 |
| US-20100249105-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | TBXA2R 419/4885HDAC1 1752/4885HDAC6 2598/4885 |
| US-20230414490-A1 | FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF | OPRL1, OPRK1, OPRM1 | TBXA2R 682/4885HDAC1 2715/4885HDAC6 245/4885 |
| US-10357449-B2 | — | OPRL1, OPRK1, OPRM1 | TBXA2R 690/4885HDAC1 1932/4885HDAC6 222/4885 |
| US-12303592-B2 | Formulations for parenteral delivery of compounds and uses thereof | OPRL1, OPRK1, OPRM1 | TBXA2R 682/4885HDAC1 2715/4885HDAC6 245/4885 |
| US-20100120813-A1 | PERIPHERAL OPIOID RECEPTOR ANTAGONISTS AND USES THEREOF | OPRL1, OPRM1, OPRK1 | TBXA2R 144/4885HDAC1 1670/4885HDAC6 1407/4885 |
| US-20080070975-A1 | Formulations for parenteral delivery of compounds and uses thereof | OPRL1, OPRK1, OPRM1 | TBXA2R 682/4885HDAC1 2715/4885HDAC6 245/4885 |
| US-20100087471-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | TBXA2R 419/4885HDAC1 1752/4885HDAC6 2598/4885 |
| US-20100249169-A1 | FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF | OPRL1, OPRK1, OPRM1 | TBXA2R 682/4885HDAC1 2715/4885HDAC6 245/4885 |
| US-20150353550-A1 | INDOLE AND INDOLINE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | TBXA2R 419/4885HDAC1 1752/4885HDAC6 2598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.